Results 1 to 10 of about 35,850 (107)

Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy [PDF]

Frontiers in Radiology, 2023
Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Houman Sotoudeh, Mohammadreza Alizadeh, Ramin Shahidi, Parnian Shobeiri, Zahra Saadatpour, C. Austin Wheeler, Marissa Natelson Love, Manoj Tanwar   +7 more
doaj   +4 more sources

Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment [PDF]

Pharmaceuticals
Background: Anti-amyloid therapies (AAT) are reshaping the therapeutic landscape of Alzheimer’s disease (AD), yet their implementation remains constrained by the risk of amyloid-related imaging abnormalities (ARIA).
Marialuisa Zedde, Mattia Losa, Andrea Donniaquio, Ilaria Gandoglia, Massimo Del Sette, Luca Roccatagliata, Fabrizio Piazza, Matteo Pardini, Rosario Pascarella   +8 more
doaj   +2 more sources

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +3 more sources

Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real‐world safety data, with a special focus on amyloid‐related imaging abnormalities ...
Alexander Wallace, Oliver Zhou, Minh‐Nguyet Hoang, Gabriella Porter, Claudia Padilla, Cindy Marshall   +5 more
doaj   +2 more sources

Spontaneous and Drug-Induced Amyloid-Related Imaging Abnormalities: Overlaps, Divergences, and Clinical Implications Across a Continuum Between Alzheimer’s Disease and Cerebral Amyloid Angiopathy [PDF]

Biomolecules
Background: Amyloid-related imaging abnormalities (ARIA) have gained significance in the context of anti-amyloid therapies (AATs), exhibiting clinical and radiological manifestations that overlap with Cerebral Amyloid Angiopathy-related inflammation (CAA-
Marialuisa Zedde, Mattia Losa, Elena Grisafi, Davide D. Lucia, Ilaria Gandoglia, Massimo Del Sette, Matteo Pardini, Luca Roccatagliata, Rosario Pascarella, Fabrizio Piazza   +9 more
doaj   +2 more sources

Amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease: from pathophysiology to individualized risk assessment [PDF]

Alzheimer’s Research & Therapy
Monoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease. While amyloid-targeting therapies mitigate the progression of cognitive decline in early-stage Alzheimer’s disease, they are associated ...
Jonathan Merkel, Robert Perneczky, Frank Jessen, Lutz Frölich, Olav Jansen, Sönke Peters, Daniela Berg, Jörg B. Schulz, Thorsten Bartsch   +8 more
doaj   +2 more sources

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6 [PDF]

The Journal of Prevention of Alzheimer's Disease
The TRAILBLAZER-ALZ 6 study (NCT05738486) evaluated the effect of different donanemab dosing regimens on amyloid-related imaging abnormalities with edema/sulcal effusions (ARIA-E).
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, Rashna Khanna, Diana Otero Svaldi, Sergey Shcherbinin, Wen Xu, Scott W. Andersen, Paula M. Hauck, Dawn A. Brooks, Emily C. Collins, Stephen Salloway, Mark A. Mintun, John R. Sims   +13 more
doaj   +2 more sources

Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications [PDF]

Frontiers in Neuroscience
Alzheimer’s disease (AD) affects over 6 million people over the age of 65. The advent of new anti-amyloid monoclonal antibodies as treatment for early Alzheimer’s disease these immunotherapeutics may slow disease progression but also pose significant ...
Sarah J. Doran, Russell P. Sawyer
doaj   +2 more sources

Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer’s disease and a literature review [PDF]

BMC Neurology
Objective To investigate the imaging characteristics and management strategies of amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease (AD) patients treated with lecanemab.
Yingte Wang, Qun Yu, Bin Chen, Jing Zhou, Zhiming Li, Wang Liao, Jun Liu, Airong Yang   +7 more
doaj   +2 more sources

Amyloid‐related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid‐modifying therapy [PDF]

Annals of Clinical and Translational Neurology
Amyloid‐related imaging abnormalities, were originally described by dementia care experts. The wider use of aducanumab and now lecanemab warrant broader understanding by the health care provider continuum.
Rade B. Vukmir
doaj   +2 more sources